Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24812981 | 1.00 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL2928741 | 1.00 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL3105701 | 0.86 | MGAM (0.41) | — | |
| SCHEMBL3093107 | 0.84 | GUSB (0.38) | — | |
| SCHEMBL3097827 | 0.82 | GUSB (0.41) | — | |
| SCHEMBL3089462 | 0.79 | FUCA1 (0.33) | FUCA1 | |
| SCHEMBL3590322 | 0.79 | FUCA1 (0.33) | FUCA1 | |
| SCHEMBL18569094 | 0.79 | FUCA1 (0.33) | FUCA1 | |
| SCHEMBL18580080 | 0.78 | GBA1 (0.37) | FUCA1 | |
| SCHEMBL4463519 | 0.78 | ALOX15 (0.31) | FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | Amgen Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183418-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-8980965-B2 | Method for producing polyester type flexible polyurethane foam, and catalyst composition to be used therefor | TOSOH CORPORATION (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | TOSOH CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204394-A1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | Tosoh Corporation (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-RE41315-E1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1419773-B1 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| EP-0861660-B9 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORP (JP) | 2006-06-28 | — | — | EP | disclosed |
| US-6924374-B2 | Central nervous system disorders; psychological disorders | A. CARLSSON RESEARCH AB (SE) | 2005-08-02 | — | — | US | disclosed |
| EP-0787494-B1 | Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori | KANEKA CORP (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1419773-A2 | 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1240141-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030109532-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2003-06-12 | — | — | US | disclosed |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2003-01-02 | — | — | US | disclosed |
| US-5981522-A | ADMINISTERING RIFAMYCIN DERIVATIVE TO THE PATIENT TO TREAT GASTRITIS, GASTRODUODENITIS, EROSIVE GASTRITIS, GASTRIC EROSION, EROSIVE DUODENITIS, GASTRIC ULCER AND DUODENAL ULCER CAUSED BY HELICOBACTER PLORI | KANEKA CORPORATION (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0861660-A1 | Curative medicine for disease caused by infection of Helicobacter | KANEKA CORPORATION (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0787494-A1 | REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER | KANEKA CORPORATION (JP) | 1997-08-06 | — | — | EP | disclosed |
| US-4138566-A | Piperazinyl cyclobutenones | G. D. SEARLE & CO. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4036828-A | 3,4-Bis(4-substituted piperazinyl)-3-cyclobutene-1,2-diones and related compounds | G. D. SEARLE & CO. (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109532-A1 | Modulators of dopamine neurotransmission | OPRD1, CHRNA5, OPRM1 | FUCA1 2894/4885 |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | OR51E2, CYP4F11, FFAR3 | FUCA1 4083/4885 |
| US-20030004169-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | FUCA1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.